European Urology, Год журнала: 2024, Номер unknown
Опубликована: Окт. 1, 2024
Язык: Английский
PeerJ, Год журнала: 2024, Номер 12, С. e18636 - e18636
Опубликована: Дек. 5, 2024
CYP3A, a key member of the cytochrome P450 (CYP450) superfamily, is integral to drug metabolism, processing substantial portion medications. Their role in metabolism particularly prominent, as CYP3A4 and CYP3A5 metabolize approximately 30–50% known drugs. The genetic polymorphism CYP3A4/5 significant inter-individual variability enzymatic activity, which can result different pharmacokinetic profiles response same among individuals. These polymorphisms lead either increased toxicity or reduced therapeutic effects, requiring dosage adjustments based on profiles. Consequently, study activity gene variants great importance for formulation personalized treatment regimens. This article first reviews human body, including inhibitors inducers drug-drug interactions. In terms polymorphism, it discusses detection methods, kinetic characteristics, clinical guidelines CYP3A5. Finally, summarizes applications, therapy, management interactions, adjustment doses. review contributes understanding functions characteristics CYP3A4/5, allowing more effective outcomes through optimized therapy.
Язык: Английский
Процитировано
4
Cancers, Год журнала: 2025, Номер 17(2), С. 279 - 279
Опубликована: Янв. 16, 2025
Background: Prostate cancer (PCa) accounts for 22% of the new cases diagnosed in Hispanic/Latino (H/L) men US. PCa has highest incidence (38.3%) and mortality (16.4%) among all types Puerto Rico. We previously showed that patients (n = 41) have a significant reduction 59% their levels DNA repair capacity (DRC) when compared to controls 14). This study aimed evaluate DRC through nucleotide excision (NER) pathway first time 16 Rican H/L with metastatic castration-resistant (mCRPCa) while establishing comparisons indolent aggressive disease. Methods: Blood samples clinicopathological data from 71) 25) were evaluated. stratified into mCRPCa 16), 31), 24). NER measured lymphocytes CometChip assay. The stratification by Gleason score (GS) was GS6 7), GS7 23), GS ≥ 8 20), 16). Results: Significant statistical differences found comparing values any other four patient groups. had lowest mean level groups studied. 6.65%, controls, this represented statistically 62% (p < 0.0001). Further analysis performed contributions age, anthropometric measurements, prostate-specific antigen (PSA) DRC. Kaplan–Meier curves revealed survival probability decreased approximately 50% 30 months. pilot uses blood-based phenotypic assay present report at global patients. Conclusions: evaluated mCRPCa. between three months, only 20% cohort alive 50 confirming lethality population. represents using
Язык: Английский
Процитировано
0
International Journal of Urology, Год журнала: 2025, Номер unknown
Опубликована: Фев. 25, 2025
The incidence of prostate cancer (PC) has recently increased in Japan. Androgen deprivation therapy (ADT) been a key treatment patients with castration-sensitive PC (CSPC); however, resistance typically emerges through multiple mechanisms, leading to metastatic castration-resistant (mCRPC). Taxane-based (i.e., docetaxel, cabazitaxel) standard care mCRPC. New evidence supporting the addition androgen receptor signaling inhibitors (ARSIs, e.g., enzalutamide, abiraterone) docetaxel and ADT for CSPC (mCSPC) raises questions about role taxane-based therapies their optimal sequencing, as well how identify who may benefit from therapy. Here we review on therapy, including cabazitaxel, PC, focus clinical real-world Cabazitaxel proven effective mCRPC have history ARSI use, it is preferable second alternative ARSI, indicated CARD study. safety profile cabazitaxel (particularly, neutropenia) can be managed prophylactic use granulocyte colony-stimulating factor, lower dosage possibly variation interval. However, certain dose intensity required because neutropenia identified potential prognostic indicator effectiveness. In era mCSPC, sequencing limited. A better understanding biology collection data essential improved safety-benefit outcomes.
Язык: Английский
Процитировано
0
EClinicalMedicine, Год журнала: 2025, Номер 81, С. 103129 - 103129
Опубликована: Фев. 28, 2025
Язык: Английский
Процитировано
0
Life Sciences, Год журнала: 2025, Номер 372, С. 123646 - 123646
Опубликована: Апрель 17, 2025
Язык: Английский
Процитировано
0
European Urology, Год журнала: 2024, Номер unknown
Опубликована: Окт. 1, 2024
Язык: Английский
Процитировано
1